MoonLake Immunotherapeutics (MLTX) Net Cash Flow Growth (3y) (2024 - 2026)
MoonLake Immunotherapeutics (MLTX) Net Cash Flow Growth (3y) (2024 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,102.16 Bn | 67,101.87 Bn | - | -50.33% |
| 2 | Nanobiotix | 1,913.50 Bn | 1,913.44 Bn | - | - |
| 3 | Akari Therapeutics | 959.56 Bn | 959.56 Bn | - | - |
| 4 | BeOne Medicines | 473.74 Bn | 468.95 Bn | 1.35 Bn | 38.47% |
| 5 | Vertex Pharmaceuticals | 122.07 Bn | 114.82 Bn | 2.59 Bn | 33.37% |
| 6 | Regeneron Pharmaceuticals | 70.00 Bn | 61.24 Bn | 3.31 Bn | -29.82% |
| 7 | Belite Bio | 62.34 Bn | 62.34 Bn | - | - |
| 8 | Argenx Se | 55.96 Bn | 50.77 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.49 Bn | 34.48 Bn | 959.66 Mn | 32.17% |
| 10 | MoonLake Immunotherapeutics | 1.42 Bn | 1.06 Bn | - | -74.85% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -74.85% |
| Dec 31, 2025 | -112.87% |
| Sep 30, 2025 | 41.94% |
| Jun 30, 2025 | -26.21% |
| Mar 31, 2025 | 384.56% |
| Dec 31, 2024 | -197.55% |
| Sep 30, 2024 | 187.10% |
| Jun 30, 2024 | -277.80% |
| Mar 31, 2024 | 257.18% |